Comparative Role of Angiotensin Receptor Blockers Versus Other Agents in the Management of Hypertension, Cardiovascular Disease and Nephropathy

2009 ◽  
Vol 102 (12) ◽  
pp. 1201-1202
Author(s):  
Michael W. Tempelhof
Keyword(s):  
Cardiovascular Disease ◽  
Angiotensin Receptor Blockers ◽  
Angiotensin Receptor ◽  
Receptor Blockers

The Evolving Role of Angiotensin Receptor Blockers in Heart Failure

2002 ◽  
Vol 37 (5) ◽  
pp. 474-482
Author(s):  
Patricia A. Howard
Keyword(s):  
Heart Failure ◽  
Cardiovascular Disease ◽  
Angiotensin Receptor Blockers ◽  
Angiotensin Receptor ◽  
Cardiovascular Pharmacotherapy ◽  
The Us ◽  
Prevention And Treatment ◽  
Recent Developments ◽  
Receptor Blockers

This continuing feature will update readers on recent developments in cardiovascular pharmacotherapy. Cardiovascular disease remains the number one killer in the US, and more clinical outcome trials have been conducted in cardiology than in any other field of medicine. Given this rapidly expanding knowledge base, pharmacists can have a significant impact on the prevention and treatment of cardiovascular disease—if they keep current with developments in drug therapy.

Telmisartan in High Cardiovascular Risk Patients

2012 ◽  
Vol 8 (1) ◽  
pp. 10 ◽  
Author(s):  
Roland Asmar ◽  
Keyword(s):  
Cardiovascular Disease ◽  
Cardiovascular Risk ◽  
Ace Inhibitors ◽  
Angiotensin Receptor Blockers ◽  
High Cardiovascular Risk ◽  
Raas Blockade ◽  
Risk Patients ◽  
Receptor Blockers ◽  
Current Guidelines

The worldwide morbidity and mortality burden of cardiovascular disease (CVD) is overwhelming and caused by increasing life expectancy and an epidemic of risk factors, including hypertension. Therapeutic options targeting different areas of the renin–angiotensin–aldosterone system (RAAS) to disrupt pathophysiological processes along the cardiovascular continuum are available. Angiotensin-converting enzyme (ACE) inhibitors are first-line treatments for CVD and angiotensin receptor blockers (ARBs) are suitable alternatives. Both ACE inhibitors and ARBs prevent CVD by lowering blood pressure (BP). Additionally, several studies have demonstrated that RAAS blockade can reduce cardiovascular risk beyond what might be expected from BP lowering alone. However, the ARBs are not all equally effective. Telmisartan is a long-lasting ARB that effectively controls BP over the full 24-hour period. Recently, the Ongoing telmisartan alone and in combination with ramipril global endpoint trial (ONTARGET) study showed that telmisartan reduces cardiovascular events in high cardiovascular risk patients similarly to the gold standard ACE inhibitor ramipril beyond BP lowering alone, but with a better tolerability. Based on the results of the ONTARGET and Telmisartan randomized assessment study in ACE intolerant subjects with cardiovascular disease (TRANSCEND) studies, telmisartan is indicated for the reduction of cardiovascular morbidity. This article aims to review current guidelines for the management of CVD and consider key data from clinical trials and clinical practice evaluating the role of telmisartan in CVD.

Drug Interactions with Angiotensin Receptor Blockers: Role of Human Cytochromes P450

2016 ◽  
Vol 17 (7) ◽  
pp. 681-691 ◽  
Author(s):  
Ruirui Yang ◽  
Zhiqiang Luo ◽  
Yang Liu ◽  
Mohan Sun ◽  
Ling Zheng ◽  
...  
Keyword(s):  
Drug Interactions ◽  
Cytochromes P450 ◽  
Angiotensin Receptor Blockers ◽  
Angiotensin Receptor ◽  
Receptor Blockers

scholarly journals Azilsartan: Current Evidence and Perspectives in Management of Hypertension

2019 ◽  
Vol 2019 ◽  
pp. 1-8
Author(s):  
Akshyaya Pradhan ◽  
Ashish Tiwari ◽  
Rishi Sethi
Keyword(s):  
Antihypertensive Drugs ◽  
Angiotensin Receptor Blockers ◽  
Financial Burden ◽  
Daily Practice ◽  
Current Evidence ◽  
Hypertension Management ◽  
Angiotensin Receptor ◽  
Global Pandemic ◽  
Receptor Blockers

Hypertension continues to be global pandemic with huge mortality, morbidity, and financial burden on the health system. Unfortunately, most patients with hypertension would eventually require two or more drugs in combination to achieve their target blood pressure (BP). To this end, emergence of more potent antihypertensive drugs is a welcome sign. Angiotensin receptor blockers (ARBs) are cornerstones of hypertension management in daily practice. Among all ARBs, azilsartan is proven to be more potent in most of the head-to-head trials till date. Azilsartan is the latest ARB approved for hypertension with greater potency and minimal side effects. This review highlights the role of azilsartan in management of hypertension in the current era.

The role of angiotensin receptor blockers in CVD risk management

2020 ◽  
Vol 18 (4) ◽  
pp. 181-185 ◽  
Author(s):  
Leonardo Grabinski Bottino ◽  
Flávio Danni Fuchs
Keyword(s):  
Risk Management ◽  
Angiotensin Receptor Blockers ◽  
Angiotensin Receptor ◽  
Cvd Risk ◽  
Receptor Blockers
Sign in / Sign up

Export Citation Format

Share Document